R
REGENXBIO Inc.
RGNX · NASDAQ · Healthcare · 557M
Closing price
$8.07
-0.25% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
4.1×
Enterprise value / EBITDAEV/EBITDA
-4.8×
Free cash flow yieldFCF yield
-30.4%
Return on equityROE
-188.7%
Operating margin
-94.6%
Net debt / EBITDAbalance-sheet strength
-1.7×
Interest coverage
-3.6×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.